Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Interest Expenses (2023 - 2024)

Oramed Pharmaceuticals' Interest Expenses history spans 2 years, with the latest figure at $261000.0 for Q2 2024.

  • For Q2 2024, Interest Expenses changed N/A year-over-year to $261000.0; the TTM value through Jun 2025 reached $261000.0, down 90.97%, while the annual FY2024 figure was $853000.0, 58.12% down from the prior year.
  • Interest Expenses reached $261000.0 in Q2 2024 per ORMP's latest filing, down from $592000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.2 million in Q4 2023 to a low of $261000.0 in Q2 2024.